Compare SMHI & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMHI | HELP |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 233.0M |
| IPO Year | 2016 | N/A |
| Metric | SMHI | HELP |
|---|---|---|
| Price | $8.35 | $6.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 170.1K | ★ 1.5M |
| Earning Date | 04-29-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $173,783,000.00 | N/A |
| Revenue This Year | $1.21 | N/A |
| Revenue Next Year | $9.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.70 | $3.76 |
| 52 Week High | $8.47 | $8.55 |
| Indicator | SMHI | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 62.60 |
| Support Level | $6.89 | $5.77 |
| Resistance Level | N/A | $7.06 |
| Average True Range (ATR) | 0.48 | 0.53 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 88.73 | 70.36 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.